FernandoCostaSantiniMD

PubMed

• Brazilian Expert Consensus for NTRK Gene Fusion Testing in Solid Tumors.
  Mariana Petaccia de Macedo, Ellen Caroline Toledo Nascimento, Fernando Augusto Soares, Fernando Costa Santini, Felipe D'Almeida Costa, Isabela Werneck da Cunha, Rodrig...> ;Clinical Pathology. 2023 Sep 15
• 6 citations
  Clinical and Genomic Features of Response and Toxicity to Sotorasib in a Real-World Cohort of Patients With Advanced-Mutant Non-Small Cell Lung Cancer.
  Rohit Thummalapalli, Ezra Bernstein, Benjamin Herzberg, Bob T Li, Afsheen Iqbal, Isabel Preeshagul, Fernando C Santini, Juliana Eng, Marc Ladanyi, Soo-Ryum Yang, Rongl...> ;JCO Precision Oncology. 2023 Jun 1
• 2 citations
  Radiogenomics in personalized management of lung cancer patients: Where are we?
  Jose Arimateia Batista Araujo-Filho, Maria Mayoral, Natally Horvat, Fernando C Santini, Peter Gibbs, Michelle S Ginsberg> ;Clinical Imaging. 2022 Apr 1
• 4 citations
  Direct Oral Anticoagulants for the Treatment of Cancer-Associated Venous Thromboembolism: A Latin American Perspective.
  Rodrigo Abensur Athanazio, José Manuel Ceresetto, Luis Javier Marfil Rivera, Gabriela Cesarman-Maus, Kenny Galvez, Marcos Arêas Marques, Aldo Hugo Tabares, Carlos Albe...> ;Clinical and Applied Thrombosis/hemostasis. 2022 Mar 9
• 19 citations
  NTRK fusions in lung cancer: From biology to therapy.
  Guilherme Harada, Fernando C. Santini, Clare Wilhelm, Alexander Drilon> ;Lung Cancer. 2021 Nov 1
• 4 citations
  Identification of the TP53 p.R337H Variant in Tumor Genomic Profiling Should Prompt Consideration of Germline Testing for Li-Fraumeni Syndrome
  Renata Lazari Sandoval, Cibele Masotti, Mariana Petaccia de Macedo, Maurício Fernando Silva Almeida Ribeiro, Ana Carolina Rathsam Leite, Sibele I. Meireles, Rodrigo Me...> ;JCO Global Oncology. 2021 Jul 16
• 23 citations
  Phase III study of selpercatinib versus chemotherapy ± pembrolizumab in untreated RET positive non-small-cell lung cancer.
  Benjamin Solomon, C. Zhou, Alexander Drilon, Keunchil Park, Jürgen Wolf, Yasir Elamin, Hannah M Davis, Victoria Soldatenkova, Andreas Sashegyi, Aimee Bence Lin, Boris ...> ;Future Oncology. 2021 Mar 1
• 14 citations
  TRK Inhibitors in Non-Small Cell Lung Cancer.
  Guilherme Harada, Aline Bobato Lara Gongora, Cesar Martins da Costa, Fernando Costa Santini> ;Current Treatment Options in Oncology. 2020 Apr 23
• 128 citations
  Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC)
  Ana C.Z. Gelatti, Alexander Drilon, Fernando C. Santini> ;Lung Cancer. 2019 Nov 1
• 2 citations
  Successful osimertinib rechallenge following drug-induced pneumonitis after previous anti-PDL1 exposure.
  Guilherme Harada, Fernando C. Santini, Felipe Sales Nogueira Amorim Canedo, Leandro Jonata de Carvalho Oliveira, Henrique Bortot Zuppani, Gilberto de Castro> ;Ecancermedicalscience. 2019 Oct 21
• 225 citations
  Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC.
  Fernando C. Santini, Hira Rizvi, Andrew J. Plodkowski, Andy Ni, Mario E. Lacouture, Maya Gambarin-Gelwan, Olivia Wilkins, Elizabeth Panora, Darragh Halpenny, Niamh Lon...> ;Cancer Immunology Research. 2018 Sep 1
• 30 citations
  Clinical outcomes of patients with resected, early-stage ALK-positive lung cancer.
  Jamie E. Chaft, Ibiayi Dagogo-Jack, Fernando C. Santini, Juliana Eng, Beow Y. Yeap, Benjamin Izar, Emily Chin, David R. Jones, Mark G. Kris, Alice T. Shaw, Justin F. G...> ;Lung Cancer. 2018 Aug 1
• 51 citations
  PD-1/PD-L1 Axis in Lung Cancer.
  Fernando C. Santini, Matthew D. Hellmann> ;Cancer Journal. 2018 Jan 1
• 101 citations
  Endocrine side effects of cancer immunotherapy
  Priscilla Cukier, Fernando Costa Santini, Mariana Scaranti, Ana O. Hoff> ;Endocrine-Related Cancer. 2017 Dec 1
• 30 citations
  Atezolizumab for the treatment of non-small cell lung cancer
  Fernando C. Santini, Charles M. Rudin> ;Expert Review of Clinical Pharmacology. 2017 Jul 27
• 4 citations
  Combination MET- and EGFR-directed therapy in MET-overexpressing non-small cell lung cancers: time to move on to better biomarkers?
  Fernando C. Santini, Siddharth Kunte, Alexander Drilon> ;Translational Lung Cancer Research. 2017 Jun 1
• 37 citations
  The activity, safety, and evolving role of brigatinib in patients with ALK -rearranged non-small cell lung cancers.
  Joshua K. Sabari, Fernando C. Santini, Alison M. Schram, Isabella Bergagnini, Ruqin Chen, Chebli Mrad, W. Victoria Lai, Kathryn C. Arbour, Alexander Drilon> ;Oncotargets and Therapy. 2017 Apr 6
• 25 citations
  Changing the Therapeutic Landscape in Non-small Cell Lung Cancers: the Evolution of Comprehensive Molecular Profiling Improves Access to Therapy
  Joshua K. Sabari, Fernando C. Santini, Isabella Bergagnini, W. Victoria Lai, Kathryn C. Arbour, Alexander Drilon> ;Current Oncology Reports. 2017 Apr 1
• Join now to see all